Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Acorda Therapeutics, Inc. (ACOR - Analyst Report) recently added two neuropathic pain management assets to its portfolio. The company acquired these assets, Qutenza and NP-1998 (formerly known as NGX-1998), from NeurogesX, Inc. .

Financial and Other Details

Acorda made a payment of about $8 million in return for the development and commercialization rights for Qutenza and NP-1998 in the US, Canada, Latin America and certain other territories. Acorda may pay up to another $5 million on the achievement of NP-1998 related regulatory and sales milestones.

Exclusive commercialization rights for Qutenza in the European Economic Area (EEA), certain countries in Eastern Europe, the Middle East and Africa lie with Astellas Pharma Europe Ltd., the European subsidiary of Astellas Pharma, Inc. (ALPMY). Astellas may also exercise an option to develop NP-1998 in the above-mentioned territories.

While Qutenza is approved in the US for the management of neuropathic pain associated with postherpetic neuralgia, NP-1998 is being evaluated for the treatment of neuropathic pain.

Qutenza, which was approved in the US in 2010, posted sales of $2.6 million in 2011. NeurogesX stopped promoting the product actively from Mar 2012. Acorda intends to use its existing commercial organization, including its specialty neurology sales force of about 100 sales reps, for promoting Qutenza.

Qutenza is also being evaluated as a treatment of pain associated with painful diabetic neuropathy by Astellas. It is currently in phase III development for this indication and Acorda has the right to review data from this study. Astellas and Acorda have the option to collaborate and/or split costs associated with future studies.

We are encouraged by Acorda’s efforts to expand its product portfolio and pipeline. The company has been looking towards in-licensing deals and acquisitions to expand its pipeline. In Dec 2012, Acorda acquired Neuronex and added diazepam nasal spray (management of seizure in certain epilepsy patients) to its pipeline.

Acorda currently carries a Zacks Rank #3 (Hold). At present, Biogen Idec (BIIB - Analyst Report) looks well-positioned with a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RAMBUS INC RMBS 12.36 +4.83%
BOFL HOLDING BOFI 85.10 +4.73%
DIXIE GROUP DXYN 15.33 +4.43%
DAIMLER AG DDAIF 92.96 +2.88%
ALLIANCE FIB AFOP 17.21 +2.75%